Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-63723283 (anti-PD-1) plus daratumumab vs daratumumab in relapsed or refractory multiple myeloma
2017-002611-34Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing JNJ-63723283 + daratumumab with Daratumumab alone (2 arms). Primary endpoint: Incidence of adverse events and dose-limiting toxicities. Started Aug 2017; status: completed.
02
Drugs
cetrelimabdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-002611-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002611-34.